Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80 Years: An Interim Analysis of the EXELS Study

Jean-Jacques Kiladjian,Carlos Besses,Martin Griesshammer,Luigi Gugliotta,Claire N. Harrison,Ruth Coll,Jonathan Smith,Gunnar Birgegård

Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80 Years: An Interim Analysis of the EXELS Study

2013

Jean-Jacques Kiladjian
Carlos Besses
Martin Griesshammer
Luigi Gugliotta
Claire N. Harrison
Ruth Coll
Jonathan Smith
Gunnar Birgegård

Background The median age of patients diagnosed with essential thrombocythaemia (ET) is 65–70 years but the management of very elderly patients (aged >80 years) with ET has not been well characterized.

Keywords:

Prospective cohort study
Hydroxycarbamide
Hematologic agents
Interim analysis
Pediatrics
Anagrelide
Chi-squared distribution
Medicine
Myelofibrosis
Pharmacotherapy
pharmacology toxicology
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations